Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: strong specialty segment growth and positive MSO performance are offset by declining organic parts revenue and European market challenges. The Q&A indicates cautious optimism in North America and strategic moves in Europe, but economic pressures and competition persist. Despite positive elements like AI-driven pricing and EV opportunities, the lack of clear guidance and persistent challenges suggest a neutral stock price outlook over the next two weeks.
Free Cash Flow $847 million for the full year 2025, exceeding expectations due to trade working capital initiatives. This was up from the $825 million commitment made earlier in the year.
Organic Revenue (North America) Decreased 1% on a per day basis in Q4 and 1.9% for the full year 2025. The decline was attributed to weak repairable claims, which were down approximately 10% in Q1 but improved to a range of negative 4% to 6% in Q4.
Organic Revenue (Europe) Declined 5.2% on a per day basis in Q4 and 3.9% for the full year 2025. The decline was due to weak consumer confidence, macroeconomic uncertainty, and competitive pricing pressures.
Organic Revenue (Specialty Segment) Increased 7.8% on a per day basis in Q4 and 2.7% for the full year 2025. Growth was driven by targeted initiatives to improve pricing execution and strengthen channel relationships.
Revenues $3.3 billion in Q4 2025, up 2.7% year-over-year. Growth was supported by balanced capital allocation and favorable FX and tax rates.
Diluted EPS $0.29 in Q4 2025, including a $52 million goodwill impairment related to the specialty business. Adjusted diluted EPS was $0.59, down from $0.78 in the prior year due to organic revenue declines and lower EBITDA in North America and Europe.
Segment EBITDA Margin (North America) 12.7% in Q4 2025, down 380 basis points year-over-year. The decline was due to tariff pass-through dynamics, customer mix, and the absence of a prior year nonrecurring legal settlement.
Segment EBITDA Margin (Europe) 8.3% in Q4 2025, down 180 basis points year-over-year. The decline was attributed to heightened price competition and higher input costs.
Segment EBITDA Margin (Specialty) 4.5% in Q4 2025, up 40 basis points year-over-year. Improvement was driven by strong cost control and favorable overhead leverage.
Debt $3.7 billion at year-end 2025, with leverage at 2.4x EBITDA, down sequentially. Over $500 million of debt was paid down in Q4 following the self-service divestiture and strong free cash flow generation.
Bumper to Bumper hard parts business: Continued growth in Canada with plans for further expansion in the fragmented do-it-for-me hard parts market across North America.
Specialty segment: Delivered 7.8% organic revenue growth in Q4 and 2.7% growth for the full year 2025. Sustained positive organic growth for two consecutive quarters after 14 quarters of decline.
North America market share: Gained market share by deepening relationships with MSOs and insurers, maintaining pricing discipline, and leveraging branch and distribution networks.
European market: Faced a 5.2% decline in organic revenue in Q4 and 3.9% for the full year due to weak consumer confidence, macroeconomic uncertainty, and competitive pricing pressures. Implemented aggressive pricing strategies and expanded private label inventory to protect market share.
Portfolio simplification: Completed the divestiture of the self-service segment as part of the simplification strategy.
Cost efficiencies: Streamlined key business areas, fast-tracked integration plans in Europe, and implemented targeted productivity initiatives. Approved a restructuring plan expected to save over $50 million annually, with more than half realized in 2026.
Strategic review: Initiated a comprehensive review to explore alternative structures to unlock value, given the belief that the current stock price does not reflect the company's true value.
European strategy: Focused on streamlining product lineup, sharpening go-to-market approach, and applying successful North American tactics to improve cost efficiencies and margins.
Decline in Repairable Claims: The company faced a continued decline in repairable claims, which negatively impacted organic revenue in North America. This trend, while showing some improvement, remains a challenge for the business.
Tariffs Impact: Tariffs have constrained the company's ability to fully pass through higher costs to customers, impacting margins and financial performance.
European Market Weakness: The European market experienced weak consumer confidence, macroeconomic uncertainty, and competitive pricing pressures, leading to a decline in organic revenue and EBITDA margins.
Pricing Competition in Europe: Heightened price competition in Europe has pressured gross margins and revenue, requiring aggressive pricing strategies that have short-term negative impacts.
Specialty Segment Goodwill Impairment: A $52 million goodwill impairment related to the Specialty segment was recorded, reflecting challenges in this business area.
Restructuring Costs: The company expects restructuring costs of $60 million to $70 million in 2026, which, while aimed at long-term cost savings, represent a near-term financial burden.
Supply Chain and Logistics Challenges: Efforts to streamline logistics and reduce facilities in Europe indicate ongoing challenges in optimizing the supply chain and cost structure.
Macroeconomic Uncertainty: Broader macroeconomic uncertainties, particularly in Europe, continue to weigh on consumer confidence and market conditions, impacting revenue and operational performance.
2026 EBITDA Margins: Expected to be slightly down from 2025 due to the annualization of tariff impacts.
Europe EBITDA Margins: Expected to return to near double-digit levels in 2026 with aggressive execution on strategic initiatives and further cost actions.
Specialty Segment Growth: Expected to grow closer to mid-single digits in 2026 as end markets recover.
Organic Parts and Services Revenue Growth: Projected between -0.5% and +1.5% for 2026. North America is expected to be slightly positive, Europe slightly negative, and Specialty closer to mid-single digits.
Adjusted Diluted EPS: Guided to a range of $2.90 to $3.20 for 2026.
Free Cash Flow: Expected to be between $700 million and $850 million in 2026.
Restructuring Plan: Expected to result in costs of $60 million to $70 million in 2026, generating more than $50 million in annualized cost savings, with over half realized in 2026.
Market Recovery Indicators: Positive early signs include easing insurance premium pressures, improved consumer confidence in automotive, and stabilization/improvement in used car prices, though not yet reflected in guidance.
Dividends: We returned $116 million to shareholders during the quarter through share repurchases and dividends.
Capital Return Commitment: In total, we returned $469 million to shareholders in 2025, 55% of free cash flow, exceeding the capital return commitment we outlined in our 2024 Investor Day.
Share Repurchases: We returned $116 million to shareholders during the quarter through share repurchases and dividends.
Capital Return Commitment: In total, we returned $469 million to shareholders in 2025, 55% of free cash flow, exceeding the capital return commitment we outlined in our 2024 Investor Day.
The earnings call presents mixed signals: strong specialty segment growth and positive MSO performance are offset by declining organic parts revenue and European market challenges. The Q&A indicates cautious optimism in North America and strategic moves in Europe, but economic pressures and competition persist. Despite positive elements like AI-driven pricing and EV opportunities, the lack of clear guidance and persistent challenges suggest a neutral stock price outlook over the next two weeks.
The earnings call summary and Q&A reveal mixed signals. Despite a slight revenue increase and positive specialty segment growth, challenges like decreased EPS, declining margins, and a downward revision in revenue expectations are concerning. The strategic plan to cut costs and simplify the business may mitigate some risks, but geopolitical issues and economic pressures remain. The Q&A indicates stability in Europe and leadership traction, but no significant market recovery is expected soon. The neutral sentiment reflects balanced positive and negative factors, with no strong catalysts for significant stock price movement.
The earnings call summary presents a mixed picture. Basic financial performance is stable but not exceptional, with revenue and EPS guidance at the lower end. Product development shows some positive momentum, but market strategy in Europe faces competitive pressures. Expenses are managed, but tariff impacts and cost-cutting in Europe are concerns. Shareholder return plans are unclear. Q&A insights reveal management's cautious outlook and lack of specific guidance, balancing positive and negative factors. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment rating.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.